Has Bharat Barai, MD received payments from drug or device companies?

Yes. Drug and device makers reported $596,522 in general payments to Bharat Barai, MD across 576 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bharat Barai, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bharat Barai, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bharat Barai, MD

Hematology & Oncology · Merrillville, INNPI 1649257650

Payments from drug & device makers

$596,522in general payments, 2019–2025

Across 576 payments — averaging $1035.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$538K
Eli Lilly$19K
E.r. Squibb & Sons, L.L.C.$11K
Daiichi Sankyo Inc.$7K
AstraZeneca$4K
Global Blood Therapeutics, Inc.$3K
plus $14K from 54 others

$507in research payments, 2019–2025

Across 1 payment — averaging $507.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$507

What the payments were for

Consulting fees$15,30051%
Speaking & faculty fees$2,3008%
Travel & lodging$4361%
Food & beverage$11,83539%
Education$2331%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	87	$538,318
Eli Lilly	3	$19,211
E.r. Squibb & Sons, L.L.C.	44	$10,798
Daiichi Sankyo Inc.	28	$7,096
AstraZeneca(2 entities)	41	$3,816
Global Blood Therapeutics, Inc.	4	$2,564
Karyopharm Therapeutics Inc.	1	$2,250
Bayer	8	$1,689
Rigel Pharmaceuticals, Inc.	7	$1,337
Johnson & Johnson(3 entities)	27	$845
Gilead(2 entities)	25	$810
Novartis	37	$695
Genentech USA, Inc.	25	$606
Beigene USA, Inc.	2	$559
Pfizer	30	$505
AbbVie	19	$450
Astellas Pharma US Inc	17	$435
Exelixis Inc.	11	$430
Amgen	18	$422
Sanofi	13	$246
Seagen Inc.	11	$236
Incyte Corporation	11	$173
EKOS Corporation	2	$168
Eisai Inc.	8	$161
Puma Biotechnology, Inc.	4	$159
Blueprint Medicines Corporation	2	$150
Bristol Myers Squibb	7	$133
Lexicon Pharmaceuticals, Inc.	1	$123
Boehringer Ingelheim	4	$121
GSK	5	$112
ASD Specialty Healthcare, LLC	2	$106
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$100
Jazz Pharmaceuticals Inc.	4	$99
Ipsen Biopharmaceuticals, Inc	3	$93
Biosense Webster, Inc.	1	$87
Sirtex Medical Inc	1	$86
Sumitomo Pharma America, Inc.	3	$81
Adaptive Biotechnologies Corporation	3	$77
Regeneron Healthcare Solutions, Inc.	3	$73
Epizyme, Inc.	3	$54
Lilly USA, LLC	3	$51
Deciphera Pharmaceuticals Inc.	2	$51
Tersera Therapeutics LLC	2	$48
Takeda Pharmaceuticals U.S.A., Inc.	2	$48
Array Biopharma Inc	2	$39
Springworks Therapeutics, Inc.	1	$38
Genentech, Inc.	1	$38
Pharmaessentia USA Corporation	2	$37
Emmaus Medical, Inc.	2	$36
EMD Serono, Inc.	2	$35
Syndax Pharmaceuticals, Inc.	1	$34
Caris MPI, Inc.	1	$34
AVEO Pharmaceuticals, Inc.	1	$33
Acrotech Biopharma Inc.	2	$32
Stemline Therapeutics Inc.	2	$30
Amneal Pharmaceuticals LLC	1	$27
Stryker	1	$26
Dova Pharmaceuticals	2	$26
Mayne Pharma Commercial LLC	1	$26
Foundation Medicine, Inc.	2	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CALQUENCE$2,800
Enhertu$2,776
OXBRYTA$2,530
XPOVIO$2,250
Stivarga$1,589
Tavalisse$1,200
BRUKINSA$525
MK-7339$436
Trodelvy$240
Cabometyx$240
AYVAKIT$132
Monarch Platform$131
Inpefa$123
Nerlynx$113
TRULANCE$100

How this compares

$596,522 in reported general payments places this provider in the 90th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana →

Medicare billing

Part B allowed, 2024

$400,339

Medicare patients

438

Services billed

13,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Warfarin Sodium	19	$41

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Merrillville

Geeta KurraMerrillville$76K
Gregory DurmIndianapolis$22.7M
Nabil AdraIndianapolis$13.2M
Attaya SuvannasankhaIndianapolis$8.2M
Zhentao ZhangFort Wayne$6.4M
Shadia JalalIndianapolis$4.6M
Ahad SadiqFort Wayne$4M
Ruemu BirhirayIndianapolis$4M
Richard GaynorIndianapolis$3.7M
Ebenezer KioGoshen$2.8M

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →